Holen Sie sich die Stockscreener-App
0.3987
28.27%
0.0888
Schlusskurs vom Vortag:
$0.3099
Offen:
$0.465
24-Stunden-Volumen:
331.93M
Relative Volume:
37.34
Marktkapitalisierung:
$48.22M
Einnahmen:
$297.50K
Nettoeinkommen (Verlust:
$-72.19M
KGV:
-0.2328
EPS:
-1.7127
Netto-Cashflow:
$-54.39M
1W Leistung:
+74.04%
1M Leistung:
+26.15%
6M Leistung:
-76.34%
1J Leistung:
-75.16%
1-Tages-Spanne:
$0.393
$0.5069
1-Wochen-Bereich:
$0.2198
$0.5069
52-Wochen-Spanne:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.399 | 37.46M | 297.50K | -72.19M | -54.39M | -1.7127 |
VRTX
Vertex Pharmaceuticals Inc
|
436.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.79 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.99 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.19 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.99 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
OTLK stock surges over 50% pre-market, breaches key technical milestone – what’s behind this massive rally? - MSN
OTLK - Finviz
Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Benzinga
OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone – What’s Behind This Massive Rally? - Stocktwits
Outlook Therapeutics Wins FDA Appeal, Plans June 2026 Resubmission for ONS-5010/LYTENAVA™ (Bevacizumab) for Wet AMD Approval 1 - Minichart
Outlook Therapeutics stock surges after winning FDA appeal - Investing.com
Outlook Therapeutics (OTLK) Gains FDA Appeal Approval for Lytenava - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Outlook Therapeutics says FDA finds substantial evidence of effectiveness for Lytenava in nAMD - marketscreener.com
Outlook Therapeutics wins FDA appeal, to resubmit LYTENAVA BLA in June 2026 - TradingView
[8-K] Outlook Therapeutics, Inc. Reports Material Event - Stock Titan
Outlook Therapeutics Wins Appeal Following Formal Dispute - GlobeNewswire
OTLK SEC FilingsOutlook Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Outlook Therapeutics (OTLK) seeks warrant issuances, 600M authorized shares, reverse split - Stock Titan
OTLK Technical Analysis | Trend, Signals & Chart Patterns | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
This Applied Materials analyst is no longer bullish; here are top 5 downgrades for Monday - MSN
BTIG downgrades Outlook Therapeutics (OTLK) - MSN
This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Sahm
Outlook Therapeutics Reports Second Quarter 2026 Financial Results - VisionMonday.com
OTLK Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Outlook Therapeutics Reports Q2 2026 Financial Results, Updates on FDA Review and European Expansion of LYTENAVA (bevacizumab gamma) - Minichart
BTIG downgrades Outlook Therapeutics stock rating to neutral By Investing.com - Investing.com Australia
BTIG downgrades Outlook Therapeutics stock rating to neutral - Investing.com UK
BTIG Downgrades Outlook Therapeutics to Neutral From Buy - marketscreener.com
Outlook Therapeutics reports Q2 FY2026 net loss $4.5M, adjusted net loss $14.1M; FDA decision expected May 2026 - TradingView
Outlook Therapeutics Q2 Net Loss Narrows; Expects FDA Decision For LYTENAVA In May 2026 - RTTNews
Outlook Therapeutics (OTLK) Reports Q2 Revenue Below Expectations - GuruFocus
Outlook Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Outlook Therapeutics, Inc. 3Q 2026: Revenue $127K, EPS $(0.05) — 10-Q Summary - TradingView
OTLK: Net loss of $27.5M, negative revenue, and urgent funding needs amid ongoing U.S. regulatory delays - TradingView
Outlook Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
[10-Q] Outlook Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 - marketscreener.com
Outlook Therapeutics Q2 adjusted EPS misses analyst expectations - TradingView
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
Outlook Therapeutics stock (US69012T1051): new $100 million ATM highlights financing focus - AD HOC NEWS
Outlook Therapeutics IncEnters ATM offering agreement with H.C. Wainwright for up to $100 millionSEC filing - marketscreener.com
Outlook Therapeutics Launches New $100M ATM Offering - TipRanks
Outlook Therapeutics (OTLK) registers $100M ATM offering with H.C. Wainwright - Stock Titan
Outlook Therapeuticsenters sales agreement with H.C. Wainwright to offer and sell common stock up to $100 millionSEC filing - marketscreener.com
Outlook Therapeutics (NASDAQ: OTLK) adds $100M ATM, reports $7.7M cash - Stock Titan
Outlook Therapeutics | 8-K: Current report - Moomoo
Certain Warrants of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2026. - marketscreener.com
104,614,219 Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2026. - marketscreener.com
OTLK Stock Price, Quote & Chart | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
UBS Initiates Coverage of Amneal Pharmaceuticals (AMRX) With a Bullish Outlook - Yahoo Finance
Outlook Therapeutics Reports Closing of $5.0 Million Registered Direct Offering - VisionMonday.com
Outlook Therapeutics launches public offering; shares down - MSN
OTLK Price Today: Outlook Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Certain Warrants of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Certain Options of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):